임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
25건 표시
- 1/2상모집 중단 (진행 중)· Untreated Myelodysplastic SyndromeOral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
협력: 애브비, BMS
- 1/2상모집 중단 (진행 중)· Relapsed or Refractory T-cell LymphomasA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
리드: BMS
- 1/2상모집 중단 (진행 중)· Atypical Teratoid Rhabdoid TumorTazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
협력: BMS
- 1/2상모집 중단 (진행 중)· Advanced Solid TumorsA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
리드: BMS
- 1/2상모집 중단 (진행 중)· Multiple MyelomaCOMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
협력: BMS
- 1/2상모집 중단 (진행 중)· T-Cell Large Granular Lymphocyte LeukemiaOral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
협력: BMS
- 1/2상모집 중단 (진행 중)· Highly Sensitized Prospective Kidney Transplant RecipientsCarfilzomib and Belatacept for Desensitization
협력: BMS
- 1/2상모집 중단 (진행 중)· Prostate CancerAndrogen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
협력: BMS, 리제네론
- 1/2상모집 중단 (진행 중)· Highly Sensitized Prospective Kidney Transplant RecipientsDaratumumab and Belatacept for Desensitization
협력: BMS
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaCombination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
협력: BMS, 길리어드
- 1/2상모집 중단 (진행 중)· GlioblastomaUltrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
협력: BMS
- 1/2상모집 중단 (진행 중)· MelanomaA Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
협력: BMS
- 1/2상모집 중단 (진행 중)· Metastatic Colon AdenocarcinomaSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
협력: BMS
- 1/2상모집 중단 (진행 중)· Primary MyelofibrosisA Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
리드: BMS
- 1/2상모집 중단 (진행 중)· Advanced CancerA Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
협력: BMS
- 1/2상모집 중단 (진행 중)· MesotheliomaPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
협력: BMS
- 1/2상모집 중단 (진행 중)· Prostate CancerNivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
협력: BMS
- 1/2상모집 중단 (진행 중)· Prostate CancerCombination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
협력: BMS
- 1/2상모집 중단 (진행 중)· Esophageal CancerSafety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
협력: BMS
- 1/2상모집 중단 (진행 중)· Grade 3a Follicular LymphomaNivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
협력: BMS
- 1/2상모집 중단 (진행 중)· Hodgkin LymphomaA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
협력: BMS
- 1/2상모집 중단 (진행 중)· Triple-Negative Breast CancerCisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
협력: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.